Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses

Current Pharmaceutical Biotechnology

Volumn 12, Issue 6, 2011, Pages 867-883

  Kohan, R ^a   Cismondi, I A ^a   Oller Ramirez, A M ^a   Guelbert, N ^a   Anzolini, V Tapia ^a   Alonso, G ^a   Mole, S E ^b   de Kremer, R Dodelson ^a   de Halac, I Noher ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Enzyme replacement; Gene; Immune; Lysosomal storage diseases; Neuronal ceroid lipofuscinoses; Pharmacological; Stem cell; Therapies

Indexed keywords

ACETYLCYSTEINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; BREFELDIN A; CLENBUTEROL; EGIS 8332; LIPOFUSCIN; MERCAPTAMINE; MIGLUSTAT; MILDRONATE; MYCOPHENOLIC ACID; PREDNISOLONE; TALAMPANEL; UNCLASSIFIED DRUG; ZK 187638;

ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CLINICAL ASSESSMENT; DIET THERAPY; ENZYME REPLACEMENT; GENE THERAPY; HUMAN; IMMUNOTHERAPY; IN UTERO STEM CELL TRANSPLANTATION; LOW DRUG DOSE; NEURAL STEM CELL TRANSPLANTATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PHENOTYPE; VISUAL IMPAIRMENT;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HUMANS; MUTATION; NEURONAL CEROID-LIPOFUSCINOSES; PHENOTYPE; POLYMORPHISM, GENETIC;

ANIMALIA;

EID: 79956262686     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795542633     Document Type: Article

References (183)

1. Goebel, H. H. Wisniewski, K. E. Current state of clinical andmorphological features in human NCL. Brain Pathol., 2004, 14(1), 61-69.
2. Williams, R. E. Aberg, L. Autti, T. Goebel, H. H. Kohlschutter, A. Lonnqvist, T. Diagnosis of the neuronal ceroid lipofuscinoses:an update. Biochim. Biophys. Acta, 2006, 1762(10), 865-872.
3. Jalanko, A. Braulke, T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta, 2009, 1793(4), 697-709.
4. Mole, S. E. Williams, R. E. Goebel, H. H. Correlations betweengenotype, ultrastructural morphology and clinical phenotype in theneuronal ceroid lipofuscinoses. Neurogenetics., 2005, 6(3), 107-126.
5. Seehafer, S. S. Pearce, D. A. You say lipofuscin, we say ceroid:defining autofluorescent storage material. Neurobiol. Aging, 2006, 27(4), 576-588.
6. Haltia, M. The neuronal ceroid-lipofuscinoses: from past to present. Biochim. Biophys. Acta, 2006, 1762(10), 850-856.
7. Kyttala, A. Lahtinen, U. Braulke, T. Hofmann, S. L. Functionalbiology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim. Biophys. Acta, 2006, 1762(10), 920-933.
8. Williams, R. E. Aberg, L. Autti, T. Goebel, H. H. Kohlschutter, A. Lonnqvist, T. Diagnosis of the neuronal ceroid lipofuscinoses:an update. Biochim. Biophys. Acta, 2006, 1762(10), 865-872.
9. Cooper, J. D. Russell, C. Mitchison, H. M. Progress towards understandingdisease mechanisms in small vertebrate models of neuronalceroid lipofuscinosis. Biochim. Biophys. Acta, 2006, 1762(10), 873-889.
10. Goebel, H. H. Wisniewski, K. E. Current state of clinical and morphologicalfeatures in human NCL. Brain Pathol., 2004, 14(1), 61-69.
11. Kohlschutter, A. Schulz, A. Towards understanding the neuronalceroid lipofuscinoses. Brain Dev., 2009, 31(7), 499-502.
12. Siintola, E. Partanen, S. Stromme, P. Haapanen, A. Haltia, M. Maehlen, J. Lehesjoki, A.E. Tyynela, J. Cathepsin D deficiencyunderlies congenital human neuronal ceroid-lipofuscinosis. Brain, 2006, 129(Pt 6), 1438-1445.
13. Steinfeld, R. Reinhardt, K. Schreiber, K. Hillebrand, M. Kraetzner, R. Bruck, W. Saftig, P. Gartner, J. Cathepsin D deficiencyis associated with a human neurodegenerative disorder. Am. J. Hum. Genet., 2006, 78(6), 988-998.
14. Fritchie, K. Siintola, E. Armao, D. Lehesjoki, A. E. Marino, T. Powell, C. Tennison, M. Booker, J. M. Koch, S. Partanen, S. Suzuki, K. Tyynela, J. Thorne, L. B. Novel mutation and the firstprenatal screening of cathepsin D deficiency (CLN10). Acta Neuropathol., 2009, 117(2), 201-208.
15. Simonati, A. Tessa, A. Bernardina, B. D. Biancheri, R. Veneselli, E. Tozzi, G. Bonsignore, M. Grosso, S. Piemonte, F. Santorelli, F. M. Variant late infantile neuronal ceroid lipofuscinosis becauseof CLN1 mutations. Pediatr. Neurol., 2009, 40(4), 271-276.
16. van Diggelen, O. P. Thobois, S. Tilikete, C. Zabot, M. T. Keulemans, J. L. van Bunderen, P. A. Taschner, P. E. Losekoot, M. Voznyi, Y. V. Adult neuronal ceroid lipofuscinosis with palmitoylproteinthioesterase deficiency: first adult-onset patients of a childhooddisease. Ann. Neurol., 2001, 50(2), 269-272.
17. Kalviainen, R. Eriksson, K. Losekoot, M. Sorri, I. Harvima, I. Santavuori, P. Jarvela, I. Autti, T. Vanninen, R. Salmenpera, T. van Diggelen, O. P. Juvenile-onset neuronal ceroid lipofuscinosiswith infantile CLN1 mutation and palmitoyl-protein thioesterasedeficiency. Eur. J. Neurol., 2007, 14(4), 369-372.
18. Kohan, R. Cismondi, A. Dodelson de Kremer, R. Muller, V. J. Guelbert, N. Tapia Anzolini, V. Fietz, M. J. Ramírez, A. M. Halac, I. N. An integrated strategy for the diagnosis of NeuronalCeroid Lipofuscinosis types 1 (CLN1) and 2 (CLN2) in elevenLatin American patients. Clin. Genet., 2009, 76(4), 372-382.
19. Kohan, R. Muller, V. J. Fietz, M. J. Cismondi, A. Oller Ramirez, A. M. Noher de Halac, I. Novel human pathological mutations. Gene symbol: TPPI. Disease: Neuronal Ceroid Lipofuscinosis, Lateinfantile. ACCESSION HM070148. Hum. Genet., 2008, 123, 537-555.
20. Elleder, M. Dvorakova, L. Stolnaja, L. Vlaskova, H. Hulkova, H. Druga, R. Poupetova, H. Kostalova, E. Mikulastik, J. AtypicalCLN2 with later onset and prolonged course: a neuropathologicstudy showing different sensitivity of neuronal subpopulations toTPP1 deficiency. Acta Neuropathol., 2008, 116(1), 119-124.
21. Bessa, C. Teixeira, C. A. Dias, A. Alves, M. Rocha, S. Lacerda, L. Loureiro, L. Guimaraes, A. Ribeiro, M. G. CLN2/TPP1 deficiency:the novel mutation IVS7-10A>G causes intron retentionand is associated with a mild disease phenotype. Mol. Genet. Metab, 2008, 93(1), 66-73.
22. Hobert, J. A. Dawson, G. A novel role of the Batten disease geneCLN3: association with BMP synthesis. Biochem. Biophys. Res. Commun., 2007, 358(1), 111-116.
23. Haines, R. L. Codlin, S. Mole, S. E. The fission yeast model for thelysosomal storage disorder Batten disease predicts disease severitycaused by mutations in CLN3. Dis. Model. Mech., 2009, 2(1-2), 84-92.
24. Sarpong, A. Schottmann, G. Ruther, K. Stoltenburg, G. Kohlschutter, A. Hubner, C. Schuelke, M. Protracted course ofjuvenile ceroid lipofuscinosis associated with a novel CLN3 mutation(p. Y199X). Clin. Genet., 2009, 76(1), 38-45.
25. Rakheja, D. Narayan, S. B. Bennett, M. J. Juvenile neuronalceroid-lipofuscinosis (Batten disease): a brief review and update. Curr. Mol. Med., 2007, 7(6), 603-608.
26. Lyly, A. von, S. C. Heine, C. Schmiedt, M. L. Sipila, T. Jalanko, A. Kyttala, A. Novel interactions of CLN5 support molecular networkingbetween Neuronal Ceroid Lipofuscinosis proteins. BMC. Cell Biol, 2009, 10, 83.
27. Kohan, R. Cannelli, N. Aiello, C. Santorelli, F. M. Cismondi, A. Milà, M. Oller Ramirez, A. M. Noher de Halac, I. Novel humanpathological mutations. Gene symbol: CLN5. Disease: NeuronalCeroid Lipofuscinosis, Finnish variant. ACCESSION HD070030. Hum. Genet, 2008, 123, 537-555.
28. Cismondi, A. Cannelli, N. Aiello, C. Santorelli, F. M. Kohan, R. Oller Ramirez, A. M. Noher de Halac, I. Novel human pathologicalmutations. Gene symbol: CLN5. Disease: Neuronal Ceroid Lipofuscinosis, Finnish variant. ACCESSION HI1070015. Hum. Genet, 2008, 123, 537-555.
29. Bessa, C. Teixeira, C. A. Mangas, M. Dias, A. Sa Miranda, M. C. Guimaraes, A. Ferreira, J. C. Canas, N. Cabral, P. Ribeiro, M. G. Two novel CLN5 mutations in a Portuguese patient with vLINCL:insights into molecular mechanisms of CLN5 deficiency. Mol. Genet. Metab., 2006, 89(3), 245-253.
30. Cannelli, N. Nardocci, N. Cassandrini, D. Morbin, M. Aiello, C. Bugiani, M. Criscuolo, L. Zara, F. Striano, P. Granata, T. Bertini, E. Simonati, A. Santorelli, F. M. Revelation of a novel CLN5mutation in early juvenile neuronal ceroid lipofuscinosis. Neuropediatrics, 2007, 38(1), 46-49.
31. Cismondi, A. Kohan, R. Ghio, A. Oller Ramirez, A. M. Noher deHalac, I. Novel human pathological mutations. Gene symbol:CLN6. Disease: Neuronal Ceroid Lipofuscinosis, Late infantile. ACCESSION HM080059. Hum. Genet., 2008, 124, 293-324.
32. Siintola, E. Topcu, M. Kohlschutter, A. Salonen, T. Joensuu, T. Anttonen, A. K. Lehesjoki, A. E. Two novel CLN6 mutations invariant late-infantile neuronal ceroid lipofuscinosis patients ofTurkish origin. Clin. Genet., 2005, 68(2), 167-173.
33. Cannelli, N. Garavaglia, B. Simonati, A. Aiello, C. Barzaghi, C. Pezzini, F. Cilio, M. R. Biancheri, R. Morbin, M. Dalla, B. B. Granata, T. Tessa, A. Invernizzi, F. Pessagno, A. Boldrini, R. Zibordi, F. Grazian, L. Claps, D. Carrozzo, R. Mole, S. E. Nardocci, N. Santorelli, F. M. Variant late infantile ceroid lipofuscinosesassociated with novel mutations in CLN6. Biochem. Biophys. Res. Commun., 2009, 379(4), 892-897.
34. Al-Muhaizea, M. A. Al-Hassnan, Z. N. Chedrawi, A. Variant lateinfantile neuronal ceroid lipofuscinosis (CLN6 gene) in Saudi Arabia. Pediatr. Neurol., 2009, 41(1), 74-76.
35. Siintola, E. Topcu, M. Aula, N. Lohi, H. Minassian, B. A. Paterson, A. D. Liu, X. Q. Wilson, C. Lahtinen, U. Anttonen, A. K. Lehesjoki, A. E. The novel neuronal ceroid lipofuscinosisgene MFSD8 encodes a putative lysosomal transporter. Am. J Hum. Genet., 2007, 81(1), 136-146.
36. Kousi, M. Siintola, E. Dvorakova, L. Vlaskova, H. Turnbull, J. Topcu, M. Yuksel, D. Gokben, S. Minassian, B. A. Elleder, M. Mole, S. E. Lehesjoki, A. E. Mutations in CLN7/MFSD8 are acommon cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain, 2009, 132(Pt 3), 810-819.
37. Stogmann, E. El, T. S. Wagenstaller, J. Gaber, A. Edris, S. Abdelhady, A. ssem-Hilger, E. Leutmezer, F. Bonelli, S. Baumgartner, C. Zimprich, F. Strom, T. M. Zimprich, A. A novel mutationin the MFSD8 gene in late infantile neuronal ceroid lipofuscinosis. Neurogenetics., 2009, 10(1), 73-77.
38. Aldahmesh, M. A. Al-Hassnan, Z. N. Aldosari, M. Alkuraya, F. S. Neuronal ceroid lipofuscinosis caused by MFSD8 mutations: acommon theme emerging. Neurogenetics., 2009, 10(4), 307-311.
39. Aiello, C. Terracciano, A. Simonati, A. Discepoli, G. Cannelli, N. Claps, D. Crow, Y. J. Bianchi, M. Kitzmuller, C. Longo, D. Tavoni, A. Franzoni, E. Tessa, A. Veneselli, E. Boldrini, R. Filocamo, M. Williams, R. E. Bertini, E. S. Biancheri, R. Carrozzo, R. Mole, S. E. Santorelli, F. M. Mutations in MFSD8/CLN7are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Hum. Mutat., 2009, 30(3), E530-E540.
40. Reinhardt, K. Grapp, M. Schlachter, K. Bruck, W. Gartner, J. Steinfeld, R. Novel CLN8 mutations confirm the clinical and ethnicdiversity of late infantile neuronal ceroid lipofuscinosis. Clin. Genet, 2010, 77(1), 79-85.
41. Vantaggiato, C. Redaelli, F. Falcone, S. Perrotta, C. Tonelli, A. Bondioni, S. Morbin, M. Riva, D. Saletti, V. Bonaglia, M. C. Giorda, R. Bresolin, N. Clementi, E. Bassi, M. T. A novel CLN8mutation in late-infantile-onset neuronal ceroid lipofuscinosis(LINCL) reveals aspects of CLN8 neurobiological function. Hum. Mutat., 2009, 30(7), 1104-1116.
42. Cannelli, N. Cassandrini, D. Bertini, E. Striano, P. Fusco, L. Gaggero, R. Specchio, N. Biancheri, R. Vigevano, F. Bruno, C. Simonati, A. Zara, F. Santorelli, F. M. Novel mutations in CLN8in Italian variant late infantile neuronal ceroid lipofuscinosis: Anothergenetic hit in the Mediterranean. Neurogenetics., 2006, 7(2), 111-117.
43. Poet, M. Kornak, U. Schweizer, M. Zdebik, A. A. Scheel, O. Hoelter, S. Wurst, W. Schmitt, A. Fuhrmann, J. C. Planells-Cases, R. Mole, S. E. Hubner, C. A. Jentsch, T. J. Lysosomal storagedisease upon disruption of the neuronal chloride transport proteinClC-6. Proc. Natl. Acad. Sci. U. S. A, 2006, 103(37), 13854-13859.
44. Kasper, D. Planells-Cases, R. Fuhrmann, J. C. Scheel, O. Zeitz, O. Ruether, K. Schmitt, A. Poet, M. Steinfeld, R. Schweizer, M. Kornak, U. Jentsch, T. J. Loss of the chloride channel ClC-7leads to lysosomal storage disease and neurodegeneration. EMBOJ., 2005, 24(5), 1079-1091.
45. Sleat, D. E. Ding, L. Wang, S. Zhao, C. Wang, Y. Xin, W. Zheng, H. Moore, D. F. Sims, K. B. Lobel, P. Mass spectrometrybasedprotein profiling to determine the cause of lysosomal storagediseases of unknown etiology. Mol. Cell Proteomics., 2009, 8(7), 1708-1718.
46. Gdynia, H. J. Sperfeld, A. D. Ludolph, A. C. [Adult-onset neuronalceroid lipofuscinosis]. Nervenarzt, 2007, 78(2), 139-140.
47. Fealey, M. E. Edwards, W. D. Grogan, M. Orszulak, T. A. Neuronalceroid lipofuscinosis in a 31-year-old woman presenting asbiventricular heart failure with restrictive features. Cardiovasc. Pathol., 2009, 18(1), 44-48.
48. Sakajiri, K. Matsubara, N. Nakajima, T. Fukuhara, N. Makifuchi, T. Wakabayashi, M. Oyanagi, S. Kominami, E. A familywith adult type ceroid lipofuscinosis (Kufs' disease) and heart muscledisease: report of two autopsy cases. Intern. Med., 1995, 34(12), 1158-1163.
49. Schulz, A. Mousallem, T. Venkataramani, M. Persaud-Sawin, D. A. Zucker, A. Luberto, C. Bielawska, A. Bielawski, J. Holthuis, J. C. Jazwinski, S. M. Kozhaya, L. Dbaibo, G. S. Boustany, R. M. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem., 2006, 281(5), 2784-2794.
50. Schulz, A. Dhar, S. Rylova, S. Dbaibo, G. Alroy, J. Hagel, C. Artacho, I. Kohlschutter, A. Lin, S. Boustany, R. M. Impaired celladhesion and apoptosis in a novel CLN9 Batten disease variant. Ann. Neurol., 2004, 56(3), 342-350.
51. Josephson, S. A. Schmidt, R. E. Millsap, P. McManus, D. Q. Morris, J. C. Autosomal dominant Kufs' disease: a cause of earlyonset dementia. J. Neurol. Sci., 2001, 188(1-2), 51-60.
52. Nijssen, P. C. Ceuterick, C. van Diggelen, O. P. Elleder, M. Martin, J. J. Teepen, J. L. Tyynela, J. Roos, R. A. Autosomal dominantadult neuronal ceroid lipofuscinosis: a novel form of NCL withgranular osmiophilic deposits without palmitoyl proteinthioesterase 1 deficiency. Brain Pathol., 2003, 13(4), 574-581.
53. Nijssen, P. C. Brusse, E. Leyten, A. C. Martin, J. J. Teepen, J. L. Roos, R. A. Autosomal dominant adult neuronal ceroid lipofuscinosis:parkinsonism due to both striatal and nigral dysfunction. Mov. Disord., 2002, 17(3), 482-487.
54. Glass, C. K. Saijo, K. Winner, B. Marchetto, M. C. Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140(6), 918-934.
55. Pierret, C. Morrison, J. A. Kirk, M. D. Treatment of lysosomalstorage disorders: Focus on the neuronal ceroid-lipofuscinoses. Acta Neurobiol. Exp. (Wars.), 2008, 68(3), 429-442.
56. Hobert, J. A. Dawson, G. Neuronal ceroid lipofuscinoses therapeuticstrategies: past, present and future. Biochim. Biophys. Acta, 2006, 1762(10), 945-953.
57. Campeau, P. M. Scriver, C. R. Mitchell, J. J. A 25-year longitudinalanalysis of treatment efficacy in inborn errors of metabolism. Mol. Genet. Metab, 2008, 95(1-2), 11-16.
58. Platt, F. M. Lachmann, R. H. Treating lysosomal storage disorders:current practice and future prospects. Biochim. Biophys. Acta, 2009, 1793(4), 737-745.
59. Haskins, M. Gene therapy for lysosomal storage diseases (LSDs) inlarge animal models. ILAR. J, 2009, 50(2), 112-121.
60. Beck, M. Therapy for lysosomal storage disorders. IUBMB. Life, 2010, 62(1), 33-40.
61. Worgall, S. Kekatpure, M. V. Heier, L. Ballon, D. Dyke, J. P. Shungu, D. Mao, X. Kosofsky, B. Kaplitt, M. G. Souweidane, M. M. Sondhi, D. Hackett, N. R. Hollmann, C. Crystal, R. G. Neurologicaldeterioration in late infantile neuronal ceroid lipofuscinosis. Neurology, 2007, 69(6), 521-535.
62. Worgall, S. Sondhi, D. Hackett, N. R. Kosofsky, B. Kekatpure, M. V. Neyzi, N. Dyke, J. P. Ballon, D. Heier, L. Greenwald, B. M. Christos, P. Mazumdar, M. Souweidane, M. M. Kaplitt, M. G. Crystal, R. G. Treatment of late infantile neuronal ceroidlipofuscinosis by CNS administration of a serotype 2 adenoassociatedvirus expressing CLN2 cDNA. Hum. Gene Ther., 2008, 19(5), 463-474.
63. Ramadan, H. Al-Din, A. S. Ismail, A. Balen, F. Varma, A. Twomey, A. Watts, R. Jackson, M. Anderson, G. Green, E. Mole, S. E. Adult neuronal ceroid lipofuscinosis caused by deficiencyin palmitoyl protein thioesterase 1. Neurology, 2007, 68(5), 387-388.
64. Steinfeld, R. Heim, P. von, G. H. Meyer, K. Ullrich, K. Goebel, H. H. Kohlschutter, A. Late infantile neuronal ceroid lipofuscinosis:quantitative description of the clinical course in patients withCLN2 mutations. Am. J. Med. Genet., 2002, 112(4), 347-354.
65. Holmberg, V. Lauronen, L. Autti, T. Santavuori, P. Savukoski, M. Uvebrant, P. Hofman, I. Peltonen, L. Jarvela, I. Phenotypegenotypecorrelation in eight patients with Finnish variant late infantileNCL (CLN5). Neurology, 2000, 55(4), 579-581.
66. Pineda-Trujillo, N. Cornejo, W. Carrizosa, J. Wheeler, R. B. Munera, S. Valencia, A. gudelo-Arango, J. Cogollo, A. Anderson, G. Bedoya, G. Mole, S. E. Ruiz-Linares, A. A CLN5 mutationcausing an atypical neuronal ceroid lipofuscinosis of juvenileonset. Neurology, 2005, 64(4), 740-742.
67. Lebrun, A. H. Storch, S. Ruschendorf, F. Schmiedt, M. L. Kyttala, A. Mole, S. E. Kitzmuller, C. Saar, K. Mewasingh, L. D. Boda, V. Kohlschutter, A. Ullrich, K. Braulke, T. Schulz, A. Retentionof lysosomal protein CLN5 in the endoplasmic reticulumcauses neuronal ceroid lipofuscinosis in Asian sibship. Hum. Mutat., 2009, 30(5), E651-E661.
68. Siintola, E. Topcu, M. Aula, N. Lohi, H. Minassian, B. A. Paterson, A. D. Liu, X. Q. Wilson, C. Lahtinen, U. Anttonen, A. K. Lehesjoki, A. E. The novel neuronal ceroid lipofuscinosisgene MFSD8 encodes a putative lysosomal transporter. Am. J. Hum. Genet., 2007, 81(1), 136-146.
69. Zelnik, N. Mahajna, M. Iancu, T. C. Sharony, R. Zeigler, M. A novel mutation of the CLN8 gene: is there a Mediterranean phenotype? Pediatr. Neurol., 2007, 36(6), 411-413.
70. Marshall, F. J. de Blieck, E. A. Mink, J. W. Dure, L. Adams, H. Messing, S. Rothberg, P. G. Levy, E. McDonough, T. DeYoung, J. Wang, M. Ramirez-Montealegre, D. Kwon, J. M. Pearce, D. A. A clinical rating scale for Batten disease: reliable and relevant forclinical trials. Neurology, 2005, 65(2), 275-279.
71. Adams, H. R. Beck, C. A. Levy, E. Jordan, R. Kwon, J. M. Marshall, F. J. Vierhile, A. Augustine, E. F. de Blieck, E. A. Pearce, D. A. Mink, J. W. Genotype does not predict severity of behaviouralphenotype in juvenile neuronal ceroid lipofuscinosis (Battendisease). Dev. Med. Child Neurol., 2010.
72. Beck, M. New therapeutic options for lysosomal storage disorders:enzyme replacement, small molecules and gene therapy. Hum. Genet., 2007, 121(1), 1-22.
73. van Meel, E. Klumperman, J. Imaging and imagination:understanding the endo-lysosomal system. Histochem. Cell Biol, 2008, 129(3), 253-266.
74. Kornfeld, S. Mellman, I. The biogenesis of lysosomes. Annu. Rev. Cell Biol, 1989, 5, 483-525.
75. Reczek, D. Schwake, M. Schroder, J. Hughes, H. Blanz, J. Jin, X. Brondyk, W. Van, P. S. Edmunds, T. Saftig, P. LIMP-2 is areceptor for lysosomal mannose-6-phosphate-independent targetingof beta-glucocerebrosidase. Cell, 2007, 131(4), 770-783.
76. Distler, J. Hieber, V. Sahagian, G. Schmickel, R. Jourdian, G. W. Identification of mannose 6-phosphate in glycoproteins that inhibitthe assimilation of beta-galactosidase by fibroblasts. Proc. Natl. Acad. Sci. USA, 1979, 76(9), 4235-4239.
77. Kaplan, A. Achord, D. T. Sly, W. S. Phosphohexosyl componentsof a lysosomal enzyme are recognized by pinocytosis receptors onhuman fibroblasts. Proc. Natl. Acad. Sci. USA, 1977, 74(5), 2026-2030.
78. Natowicz, M. R. Chi, M. M. LOWRY, O. H. Sly, W. S. Enzymaticidentification of mannose 6-phosphate on the recognition markerfor receptor-mediated pinocytosis of beta-glucuronidase by humanfibroblasts. Proc. Natl. Acad. Sci. USA, 1979, 76(9), 4322-4326.
79. Fratantoni, J. C. Hall, C. W. Neufeld, E. F. Hurler and Hunter syndromes:mutual correction of the defect in cultured fibroblasts. Science, 1968, 162(853), 570-572.
80. Neufeld, E. F. Fratantoni, J. C. Inborn errors of mucopolysaccharidemetabolism. Science, 1970, 169(941), 141-146.
81. Sands, M. S. Davidson, B. L. Gene therapy for lysosomal storagediseases. Mol. Ther., 2006, 13(5), 839-849.
82. Desnick, R. J. Dean, K. J. Grabowski, G. A. Bishop, D. F. Sweeley, C. C. Enzyme therapy XVII: metabolic and immunologicevaluation of alpha- galactosidase A replacement in Fabry disease. Birth Defects Orig. Artic. Ser., 1980, 16(1), 393-413.
83. Desnick, R. J. Enzyme replacement and enhancement therapies forlysosomal diseases. J. Inherit. Metab Dis., 2004, 27(3), 385-410.
84. Breunig, F. Wanner, C. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J. Nephrol., 2008, 21(1), 32-37.
85. Kakkis, E. D. Muenzer, J. Tiller, G. E. Waber, L. Belmont, J. Passage, M. Izykowski, B. Phillips, J. Doroshow, R. Walot, I. Hoft, R. Neufeld, E. F. Enzyme-replacement therapy in mucopolysaccharidosisI. N. Engl. J Med., 2001, 344(3), 182-188.
86. Wraith, J. E. Clarke, L. A. Beck, M. Kolodny, E. H. Pastores, G. M. Muenzer, J. Rapoport, D. M. Berger, K. I. Swiedler, S. J. Kakkis, E. D. Braakman, T. Chadbourne, E. Walton-Bowen, K. Cox, G. F. Enzyme replacement therapy for mucopolysaccharidosisI: a randomized, double-blinded, placebo-controlled, multinationalstudy of recombinant human alpha-L-iduronidase (laronidase). J. Pediatr., 2004, 144(5), 581-588.
87. Wraith, J. E. Enzyme replacement therapy in mucopolysaccharidosistype I: progress and emerging difficulties. J. Inherit. MetabDis., 2001, 24(2), 245-250.
88. Clarke, L. A. Idursulfase for the treatment of mucopolysaccharidosisII. Expert. Opin. Pharmacother., 2008, 9(2), 311-317.
89. Harmatz, P. Giugliani, R. Schwartz, I. V. Guffon, N. Teles, E. L. Miranda, M. C. Wraith, J. E. Beck, M. Arash, L. Scarpa, M. Ketteridge, D. Hopwood, J. J. Plecko, B. Steiner, R. Whitley, C. B. Kaplan, P. Yu, Z. F. Swiedler, S. J. Decker, C. Long-termfollow-up of endurance and safety outcomes during enzyme replacementtherapy for mucopolysaccharidosis VI: Final results ofthree clinical studies of recombinant human N-acetylgalactosamine4-sulfatase. Mol. Genet. Metab., 2008, 94(4), 469-475.
90. Rohrbach, M. Clarke, J. T. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs, 2007, 67(18), 2697-2716.
91. Wang, J. Lozier, J. Johnson, G. Kirshner, S. Verthelyi, D. Pariser, A. Shores, E. Rosenberg, A. Neutralizing antibodies totherapeutic enzymes: considerations for testing, prevention andtreatment. Nat. Biotechnol., 2008, 26(8), 901-908.
92. Chen, Y. H. Chang, M. Davidson, B. L. Molecular signatures ofdisease brain endothelia provide new sites for CNS-directed enzymetherapy. Nat. Med., 2009, 15(10), 1215-1218.
93. Lin, L. Lobel, P. Production and characterization of recombinanthuman CLN2 protein for enzyme-replacement therapy in late infantileneuronal ceroid lipofuscinosis. Biochem. J., 2001, 357(Pt 1), 49-55.
94. Kakkis, E. McEntee, M. Vogler, C. Le, S. Levy, B. Belichenko, P. Mobley, W. Dickson, P. Hanson, S. Passage, M. Intrathecalenzyme replacement therapy reduces lysosomal storage in the brainand meninges of the canine model of MPS I. Mol. Genet. Metab., 2004, 83(1-2), 163-174.
95. Dickson, P. McEntee, M. Vogler, C. Le, S. Levy, B. Peinovich, M. Hanson, S. Passage, M. Kakkis, E. Intrathecal enzyme replacementtherapy: successful treatment of brain disease via thecerebrospinal fluid. Mol. Genet. Metab, 2007, 91(1), 61-68.
96. Chang, M. Cooper, J. D. Sleat, D. E. Cheng, S. H. Dodge, J. C. Passini, M. A. Lobel, P. Davidson, B. L. Intraventricular enzymereplacement improves disease phenotypes in a mouse model of lateinfantile neuronal ceroid lipofuscinosis. Mol. Ther., 2008, 16(4), 649-656.
97. Sleat, D. E. El-Banna, M. Sohar, I. Kim, K. H. Dobrenis, K. Walkley, S. U. Lobel, P. Residual levels of tripeptidyl-peptidase Iactivity dramatically ameliorate disease in late-infantile neuronalceroid lipofuscinosis. Mol. Genet. Metab., 2008, 94(2), 222-233.
98. Lu, J. Y. Hu, J. Hofmann, S. L. Human recombinant palmitoylproteinthioesterase-1 (PPT1) for preclinical evaluation of enzymereplacement therapy for infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab., 2010, 99(4), 374-378.
99. Naldini, L. Medicine. A comeback for gene therapy. Science, 2009, 326(5954), 805-806.
100. Cartier, N. Hacein-Bey-Abina, S. Bartholomae, C. C. Veres, G. Schmidt, M. Kutschera, I. Vidaud, M. Abel, U. Dal-Cortivo, L. Caccavelli, L. Mahlaoui, N. Kiermer, V. Mittelstaedt, D. Bellesme, C. Lahlou, N. Lefrere, F. Blanche, S. Audit, M. Payen, E. Leboulch, P. l'Homme, B. Bougneres, P. Von, K. C. Fischer, A. Cavazzana-Calvo, M. Aubourg, P. Hematopoieticstem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009, 326(5954), 818-823.
101. Sondhi, D. Hackett, N. R. Apblett, R. L. Kaminsky, S. M. Pergolizzi, R. G. Crystal, R. G. Feasibility of gene therapy for late neuronalceroid lipofuscinosis. Arch. Neurol., 2001, 58(11), 1793-1798.
102. Prasad, V. K. Kurtzberg, J. Cord blood and bone marrow transplantationin inherited metabolic diseases: scientific basis, current statusand future directions. Br. J. Haematol., 2010, 148(3), 356-372.
103. Muenzer, J. Fisher, A. Advances in the treatment of mucopolysaccharidosistype I. N. Engl. J. Med., 2004, 350(19), 1932-1934.
104. Griffey, M. Macauley, S. L. Ogilvie, J. M. Sands, M. S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther., 2005, 12(3), 413-421.
105. Griffey, M. A. Wozniak, D. Wong, M. Bible, E. Johnson, K. Rothman, S. M. Wentz, A. E. Cooper, J. D. Sands, M. S. CNSdirectedAAV2-mediated gene therapy ameliorates functional deficitsin a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther., 2006, 13(3), 538-547.
106. Haskell, R. E. Hughes, S. M. Chiorini, J. A. Alisky, J. M. Davidson, B. L. Viral-mediated delivery of the late-infantile neuronalceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther., 2003, 10(1), 34-42.
107. Passini, M. A. Dodge, J. C. Bu, J. Yang, W. Zhao, Q. Sondhi, D. Hackett, N. R. Kaminsky, S. M. Mao, Q. Shihabuddin, L. S. Cheng, S. H. Sleat, D. E. Stewart, G. R. Davidson, B. L. Lobel, P. Crystal, R. G. Intracranial delivery of CLN2 reduces brain pathologyin a mouse model of classical late infantile neuronal ceroidlipofuscinosis. J. Neurosci., 2006, 26(5), 1334-1342.
108. Cabrera-Salazar, M. A. Roskelley, E. M. Bu, J. Hodges, B. L. Yew, N. Dodge, J. C. Shihabuddin, L. S. Sohar, I. Sleat, D. E. Scheule, R. K. Davidson, B. L. Cheng, S. H. Lobel, P. Passini, M. A. Timing of therapeutic intervention determines functional andsurvival outcomes in a mouse model of late infantile batten disease. Mol. Ther., 2007, 15(10), 1782-1788.
109. Sondhi, D. Hackett, N. R. Peterson, D. A. Stratton, J. Baad, M. Travis, K. M. Wilson, J. M. Crystal, R. G. Enhanced survival of theLINCL mouse following CLN2 gene transfer using the rh. 10 rhesusmacaque-derived adeno-associated virus vector. Mol. Ther., 2007, 15(3), 481-491.
110. Mattson, M. P. Chan, S. L. Duan, W. Modification of brain agingand neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev., 2002, 82(3), 637-672.
111. Bennett, M. J. Boriack, R. L. Boustany, R. M. Polyunsaturated fattyacids reverse the lysosomal storage and accumulation of subunit 9of mitochondrial F1F0-ATP synthase in cultured lymphoblastsfrom patients with Batten disease. J. Inherit. Metab. Dis., 1997, 20(3), 457-460.
112. Boriack, R. L. Cortinas, E. Bennett, M. J. Mitochondrial damageresults in a reversible increase in lysosomal storage material inlymphoblasts from patients with juvenile neuronal ceroidlipofuscinosis(Batten Disease). Am. J. Med. Genet., 1995, 57(2), 301-303.
113. Neal, E. G. Chaffe, H. Schwartz, R. H. Lawson, M. S. Edwards, N. Fitzsimmons, G. Whitney, A. Cross, J. H. The ketogenic dietfor the treatment of childhood epilepsy: a randomised controlledtrial. Lancet Neurol., 2008, 7(6), 500-506.
114. Kohan, R. Noher de Halac, I. Tapia Anzolini, V. Cismondi, I. A. Oller Ramirez, A. M. Paschini Capra, A. Dodelson de Kremer, R. Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I(TPP-I) are expressed in the human saliva. A reliable and noninvasivesource for the diagnosis of infantile (CLN1) and late infantile(CLN2) neuronal ceroid lipofuscinoses. Clin. Biochem., 2005, 38(5), 492-494.
115. Zarate, C. A., Jr. Manji, H. K. The role of AMPA receptor modulationin the treatment of neuropsychiatric diseases. Exp. Neurol., 2008, 211(1), 7-10.
116. Kovacs, A. D. Weimer, J. M. Pearce, D. A. Selectively increasedsensitivity of cerebellar granule cells to AMPA receptor-mediatedexcitotoxicity in a mouse model of Batten disease. Neurobiol. Dis., 2006, 22(3), 575-585.
117. Kovacs, A. D. Pearce, D. A. Attenuation of AMPA receptor activityimproves motor skills in a mouse model of juvenile Batten disease. Exp. Neurol., 2008, 209(1), 288-291.
118. Wang, J. Y. Wen, L. L. Huang, Y. N. Chen, Y. T. Ku, M. C. Dualeffects of antioxidants in neurodegeneration: direct neuroprotectionagainst oxidative stress and indirect protection via suppression ofglia-mediated inflammation. Curr. Pharm. Des, 2006, 12(27), 3521-3533.
119. DeLegge, M. H. Smoke, A. Neurodegeneration and inflammation. Nutr. Clin. Pract., 2008, 23(1), 35-41.
120. Pupure, J. Isajevs, S. Skapare, E. Rumaks, J. Svirskis, S. Svirina, D. Kalvinsh, I. Klusa, V. Neuroprotective properties ofmildronate, a mitochondria-targeted small molecule. Neurosci. Lett., 2010, 470(2), 100-105.
121. Fan, J. Q. A counterintuitive approach to treat enzyme deficiencies:use of enzyme inhibitors for restoring mutant enzyme activity. Biol. Chem, 2008, 389(1), 1-11.
122. Loo, T. W. Clarke, D. M. Chemical and pharmacological chaperonesas new therapeutic agents. Expert. Rev. Mol. Med., 2007, 9(16), 1-18.
123. Harding, H. P. Zhang, Y. Zeng, H. Novoa, I. Lu, P. D. Calfon, M. Sadri, N. Yun, C. Popko, B. Paules, R. Stojdl, D. F. Bell, J. C. Hettmann, T. Leiden, J. M. Ron, D. An integrated stress responseregulates amino acid metabolism and resistance to oxidativestress. Mol. Cell, 2003, 11(3), 619-633.
124. Mori, K. Tripartite management of unfolded proteins in the endoplasmicreticulum. Cell, 2000, 101(5), 451-454.
125. Tessitore, A. del, P. M. Sano, R. Ma, Y. Mann, L. Ingrassia, A. Laywell, E. D. Steindler, D. A. Hendershot, L. M. d'Azzo, A. GM1-ganglioside-mediated activation of the unfolded protein responsecauses neuronal death in a neurodegenerative gangliosidosis. Mol. Cell, 2004, 15(5), 753-766.
126. Zhang, Z. Lee, Y. C. Kim, S. J. Choi, M. S. Tsai, P. C. Xu, Y. Xiao, Y. J. Zhang, P. Heffer, A. Mukherjee, A. B. Palmitoylproteinthioesterase-1 deficiency mediates the activation of the unfoldedprotein response and neuronal apoptosis in INCL. Hum. Mol. Genet., 2006, 15(2), 337-346.
127. Kim, S. J. Zhang, Z. Hitomi, E. Lee, Y. C. Mukherjee, A. B. Endoplasmicreticulum stress-induced caspase-4 activation mediatesapoptosis and neurodegeneration in INCL. Hum. Mol. Genet., 2006, 15(11), 1826-1834.
128. Kim, S. J. Zhang, Z. Lee, Y. C. Mukherjee, A. B. Palmitoyl-proteinthioesterase-1 deficiency leads to the activation of caspase-9 andcontributes to rapid neurodegeneration in INCL. Hum. Mol. Genet., 2006, 15(10), 1580-1586.
129. Farfel-Becker, T. Vitner, E. Dekel, H. Leshem, N. Enquist, I. B. Karlsson, S. Futerman, A. H. No evidence for activation of the unfoldedprotein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet., 2009, 18(8), 1482-1488.
130. Lindholm, D. Wootz, H. Korhonen, L. ER stress and neurodegenerativediseases. Cell Death. Differ., 2006, 13(3), 385-392.
131. Pastores, G. M. Miglustat: substrate reduction therapy for lysosomalstorage disorders associated with primary central nervous systeminvolvement. Recent Pat. CNS. Drug Discov., 2006, 1(1), 77-82.
132. Lachmann, R. H. te, V. D. Lloyd-Evans, E. Reinkensmeier, G. Sillence, D. J. Fernandez-Guillen, L. Dwek, R. A. Butters, T. D. Cox, T. M. Platt, F. M. Treatment with miglustat reverses the lipidtraffickingdefect in Niemann-Pick disease type C. Neurobiol. Dis., 2004, 16(3), 654-658.
133. Zervas, M. Somers, K. L. Thrall, M. A. Walkley, S. U. Critical rolefor glycosphingolipids in Niemann-Pick disease type C. Curr. Biol., 2001, 11(16), 1283-1287.
134. Chien, Y. H. Lee, N. C. Tsai, L. K. Huang, A. C. Peng, S. F. Chen, S. J. Hwu, W. L. Treatment of Niemann-Pick disease type C in twochildren with miglustat: initial responses and maintenance of effectsover 1 year. J. Inherit. Metab. Dis., 2007, 30(5), 826.
135. Zeman, R. J. Peng, H. Etlinger, J. D. Clenbuterol retards loss ofmotor function in motor neuron degeneration mice. Exp. Neurol., 2004, 187(2), 460-467.
136. Culmsee, C. Junker, V. Thal, S. Kremers, W. Maier, S. Schneider, H. J. Plesnila, N. Krieglstein, J. Enantio-selective effects ofclenbuterol in cultured neurons and astrocytes, and in a mousemodel of cerebral ischemia. Eur. J. Pharmacol., 2007, 575(1-3), 57-65.
137. Linde, L. Kerem, B. Introducing sense into nonsense in treatmentsof human genetic diseases. Trends Genet., 2008, 24(11), 552-563.
138. Welch, E. M. Barton, E. R. Zhuo, J. Tomizawa, Y. Friesen, W. J. Trifillis, P. Paushkin, S. Patel, M. Trotta, C. R. Hwang, S. Wilde, R. G. Karp, G. Takasugi, J. Chen, G. Jones, S. Ren, H. Moon, Y. C. Corson, D. Turpoff, A. A. Campbell, J. A. Conn, M. M. Khan, A. Almstead, N. G. Hedrick, J. Mollin, A. Risher, N. Weetall, M. Yeh, S. Branstrom, A. A. Colacino, J. M. Babiak, J. Ju, W. D. Hirawat, S. Northcutt, V. J. Miller, L. L. Spatrick, P. He, F. Kawana, M. Feng, H. Jacobson, A. Peltz, S. W. Sweeney, H. L. PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007, 447(7140), 87-91.
139. Schmitz, A. Famulok, M. Chemical biology: ignore the nonsense. Nature, 2007, 447(7140), 42-43.
140. Byers, P. H. Killing the messenger: new insights into nonsensemediatedmRNA decay. J. Clin. Invest., 2002, 109(1), 3-6.
141. Sleat, D. E. Sohar, I. Gin, R. M. Lobel, P. Aminoglycosidemediatedsuppression of nonsense mutations in late infantile neuronalceroid lipofuscinosis. Eur. J. Paediatr. Neurol., 2001, 5 SupplA, 57-62.
142. Edelman, A. Sermet-Gaudelus, I. Rousset, J. P. Genetic testing toprovide targeted treatment for cystic fibrosis patients. Pharmacogenomics., 2007, 8(9), 1101-1104.
143. Kim, K. H. Sleat, D. E. Bernard, O. Lobel, P. Genetic modulationof apoptotic pathways fails to alter disease course in tripeptidylpeptidase1 deficient mice. Neurosci. Lett., 2009, 453(1), 27-30.
144. Dhar, S. Bitting, R. L. Rylova, S. N. Jansen, P. J. Lockhart, E. Koeberl, D. D. Amalfitano, A. Boustany, R. M. Flupirtine blocksapoptosis in batten patient lymphoblasts and in human postmitotic. Ann. Neurol., 2002, 51(4), 448-466.
145. Klawe, C. Maschke, M. Flupirtine: pharmacology and clinicalapplications of a nonopioid analgesic and potentially neuroprotectivecompound. Expert. Opin. Pharmacother., 2009, 10(9), 1495-1500.
146. DeWitt, N. Regenerative medicine. Nature, 2008, 453(7193), 301.
147. Xu, Y. Shi, Y. Ding, S. A chemical approach to stem-cell biologyand regenerative medicine. Nature, 2008, 453(7193), 338-344.
148. Badylak, S. F. Nerem, R. M. Progress in tissue engineering andregenerative medicine. Proc. Natl. Acad. Sci. U S A, 2010, 107(8), 3285-3286.
149. Wang, J. Lu, J. Bond, M. C. Chen, M. Ren, X. R. Lyerly, H. K. Barak, L. S. Chen, W. Identification of select glucocorticoids asSmoothened agonists: potential utility for regenerative medicine. Proc. Natl. Acad. Sci. USA, 2010, 107(20), 9323-9328.
150. Parker, G. C. Blood stem cells and non-hematological clinical practice:pragmatics before therapeutics. Curr. Pharm. Biotechnol., 2007, 8(1), 51-56.
151. Boelens, J. J. Prasad, V. K. Tolar, J. Wynn, R. F. Peters, C. Currentinternational perspectives on hematopoietic stem cell transplantationfor inherited metabolic disorders. Pediatr. Clin. NorthAm., 2010, 57(1), 123-145.
152. Yuza, Y. Yokoi, K. Sakurai, K. Ariga, M. Yanagisawa, T. Ohashi, T. Hoshi, Y. Eto, Y. Allogenic bone marrow transplantationfor late-infantile neuronal ceroid lipofuscinosis. Pediatr. Int., 2005, 47(6), 681-683.
153. Lonnqvist, T. Vanhanen, S. L. Vettenranta, K. Autti, T. Rapola, J. Santavuori, P. Saarinen-Pihkala, U. M. Hematopoietic stem celltransplantation in infantile neuronal ceroid lipofuscinosis. Neurology, 2001, 57(8), 1411-1416.
154. Lake, B. D. Steward, C. G. Oakhill, A. Wilson, J. Perham, T. G. Bone marrow transplantation in late infantile Batten disease andjuvenile Batten disease. Neuropediatrics, 1997, 28(1), 80-81.
155. Wynn, R. F. Mercer, J. Page, J. Carr, T. F. Jones, S. Wraith, J. E. Use of enzyme replacement therapy (Laronidase) before hematopoieticstem cell transplantation for mucopolysaccharidosis I: experiencein 18 patients. J. Pediatr., 2009, 154(1), 135-139.
156. Deeg, H. J. Shulman, H. M. Albrechtsen, D. Graham, T. C. Storb, R. Koppang, N. Batten's disease: failure of allogeneic bone marrowtransplantation to arrest disease progression in a canine model. Clin. Genet., 1990, 37(4), 264-270.
157. Boelens, J. J. Wynn, R. F. Bierings, M. In: The EBMT-ESH Handbook; Apperley, J. Carreras, E. Gluckman, E. Gratwohl, A. Masszi, T., Eds. EBMT: Netherlands, 2008, 545-553.
158. Escolar, M. L. Poe, M. D. Provenzale, J. M. Richards, K. C. Allison, J. Wood, S. Wenger, D. A. Pietryga, D. Wall, D. Champagne, M. Morse, R. Krivit, W. Kurtzberg, J. Transplantation ofumbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med., 2005, 352(20), 2069-2081.
159. Peters, C. Charnas, L. R. Tan, Y. Ziegler, R. S. Shapiro, E. G. DeFor, T. Grewal, S. S. Orchard, P. J. Abel, S. L. Goldman, A. I. Ramsay, N. K. Dusenbery, K. E. Loes, D. J. Lockman, L. A. Kato, S. Aubourg, P. R. Moser, H. W. Krivit, W. Cerebral X-linkedadrenoleukodystrophy: the international hematopoietic cell transplantationexperience from 1982 to 1999. Blood, 2004, 104(3), 881-888.
160. Nakafuku, M. Nagao, M. Grande, A. Cancelliere, A. Revisitingneural stem cell identity. Proc. Natl. Acad. Sci. USA, 2008, 105(3), 829-830.
161. Ge, W. He, F. Kim, K. J. Blanchi, B. Coskun, V. Nguyen, L. Wu, X. Zhao, J. Heng, J. I. Martinowich, K. Tao, J. Wu, H. Castro, D. Sobeih, M. M. Corfas, G. Gleeson, J. G. Greenberg, M. E. Guillemot, F. Sun, Y. E. Coupling of cell migration withneurogenesis by proneural bHLH factors. Proc. Natl. Acad. Sci. USA, 2006, 103(5), 1319-1324.
162. Yadirgi, G. Marino, S. Adult neural stem cells and their role inbrain pathology. J. Pathol., 2009, 217(2), 242-253.
163. Cummings, B. J. Uchida, N. Tamaki, S. J. Salazar, D. L. Hooshmand, M. Summers, R. Gage, F. H. Anderson, A. J. Human neuralstem cells differentiate and promote locomotor recovery in spinalcord-injured mice. Proc. Natl. Acad. Sci. USA, 2005, 102(39), 14069-14074.
164. Hooshmand, M. J. Sontag, C. J. Uchida, N. Tamaki, S. Anderson, A. J. Cummings, B. J. Analysis of host-mediated repair mechanismsafter human CNS-stem cell transplantation for spinal cord injury:correlation of engraftment with recovery. PLoS. One., 2009, 4(6), e5871.
165. Tamaki, S. J. Jacobs, Y. Dohse, M. Capela, A. Cooper, J. D. Reitsma, M. He, D. Tushinski, R. Belichenko, P. V. Salehi, A. Mobley, W. Gage, F. H. Huhn, S. Tsukamoto, A. S. Weissman, I. L. Uchida, N. Neuroprotection of host cells by human centralnervous system stem cells in a mouse model of infantile neuronalceroid lipofuscinosis. Cell Stem Cell, 2009, 5(3), 310-319.
166. Kielar, C. Maddox, L. Bible, E. Pontikis, C. C. Macauley, S. L. Griffey, M. A. Wong, M. Sands, M. S. Cooper, J. D. Successiveneuron loss in the thalamus and cortex in a mouse model of infantileneuronal ceroid lipofuscinosis. Neurobiol. Dis., 2007, 25(1), 150-162.
167. Pontikis, C. C. Cella, C. V. Parihar, N. Lim, M. J. Chakrabarti, S. Mitchison, H. M. Mobley, W. C. Rezaie, P. Pearce, D. A. Cooper, J. D. Late onset neurodegeneration in the Cln3-/- mouse model ofjuvenile neuronal ceroid lipofuscinosis is preceded by low levelglial activation. Brain Res., 2004, 1023(2), 231-242.
168. Bible, E. Gupta, P. Hofmann, S. L. Cooper, J. D. Regional andcellular neuropathology in the palmitoyl protein thioesterase-1 nullmutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis., 2004, 16(2), 346-359.
169. Kay, G. W. Palmer, D. N. Rezaie, P. Cooper, J. D. Activation ofnon-neuronal cells within the prenatal developing brain of sheepwith neuronal ceroid lipofuscinosis. Brain Pathol., 2006, 16(2), 110-116.
170. Danton, G. H. Dietrich, W. D. Inflammatory mechanisms afterischemia and stroke. J. Neuropathol. Exp. Neurol., 2003, 62(2), 127-136.
171. Carson, M. J. Microglia as liaisons between the immune and centralnervous systems: functional implications for multiple sclerosis. Glia, 2002, 40(2), 218-231.
172. Eikelenboom, P. Bate, C. Van Gool, W. A. Hoozemans, J. J. Rozemuller, J. M. Veerhuis, R. Williams, A. Neuroinflammationin Alzheimer's disease and prion disease. Glia, 2002, 40(2), 232-239.
173. Saijo, K. Winner, B. Carson, C. T. Collier, J. G. Boyer, L. Rosenfeld, M. G. Gage, F. H. Glass, C. K. A Nurr1/CoREST pathwayin microglia and astrocytes protects dopaminergic neuronsfrom inflammation-induced death. Cell, 2009, 137(1), 47-59.
174. Katz, M. L. Sanders, D. N. Mooney, B. P. Johnson, G. S. Accumulationof glial fibrillary acidic protein and histone H4 in brain storagebodies of Tibetan terriers with hereditary neuronal ceroid lipofuscinosis. J. Inherit. Metab. Dis., 2007, 30(6), 952-963.
175. Xu, S. Sleat, D. E. Jadot, M. Lobel, P. Glial fibrillary acidic proteinis elevated in the lysosomal storage disease classical lateinfantileneuronal ceroid lipofuscinosis but is not a component ofthe storage material. Biochem. J., 2010.
176. Cook, D. N. Beck, M. A. Coffman, T. M. Kirby, S. L. Sheridan, J. F. Pragnell, I. B. Smithies, O. Requirement of MIP-1 alpha foran inflammatory response to viral infection. Science, 1995, 269(5230), 1583-1585.
177. Krathwohl, M. D. Kaiser, J. L. Chemokines promote quiescenceand survival of human neural progenitor cells. Stem Cells, 2004, 22(1), 109-118.
178. Wu, Y. P. Proia, R. L. Deletion of macrophage-inflammatory protein1 alpha retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. U S A, 2004, 101(22), 8425-8430.
179. Kielar, C. Wishart, T. M. Palmer, A. Dihanich, S. Wong, A. M. Macauley, S. L. Chan, C. H. Sands, M. S. Pearce, D. A. Cooper, J. D. Gillingwater, T. H. Molecular correlates of axonal and synapticpathology in mouse models of Batten disease. Hum. Mol. Genet., 2009, 18(21), 4066-4080.
180. Lim, M. J. Beake, J. Bible, E. Curran, T. M. Ramirez-Montealegre, D. Pearce, D. A. Cooper, J. D. Distinct patterns of serumimmunoreactivity as evidence for multiple brain-directedautoantibodies in juvenile neuronal ceroid lipofuscinosis. Neuropathol. Appl. Neurobiol., 2006, 32(5), 469-482.
181. Lim, M. J. Alexander, N. Benedict, J. W. Chattopadhyay, S. Shemilt, S. J. Guerin, C. J. Cooper, J. D. Pearce, D. A. IgG entryand deposition are components of the neuroimmune response inBatten disease. Neurobiol. Dis., 2007, 25(2), 239-251.
182. de Winter, B. C. van, G. T. Sombogaard, F. Shaw, L. M. van Hest, R. M. Mathot, R. A. Pharmacokinetic role of protein binding of mycophenolicacid and its glucuronide metabolite in renal transplantrecipients. J. Pharmacokinet. Pharmacodyn., 2009, 36(6), 541-564.
183. Aberg, L. Talling, M. Harkonen, T. Lonnqvist, T. Knip, M. Alen, R. Rantala, H. Tyynela, J. Intermittent prednisolone andautoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis. Neurology, 2008, 70(14), 1218-1220.